Changchun UP Optotech Co.,Ltd. (002338.SZ) Bundle
Curious who's positioning for growth in China's optoelectronics supply chain? Changchun UP Optotech Co.,Ltd. (002338.SZ) has drawn a broad investor base-institutional investors holding about 46.02% of shares as of September 29, 2025-while its affiliate, Changchun Changguang Chenxin Microelectronics, in which the company itself holds a 25.56% stake, has filed for an H‑share listing on the Hong Kong Stock Exchange, a move that could reshape liquidity and valuation dynamics; private equity names such as Wuhu Tuochen, Xiamen Yuanfeng Xinguang, Xianjin Zhizao Industry Investment Fund II and Yibin Chendao New Energy Industry Partnership sit among major shareholders providing capital and strategic guidance, and the company's market stature is underscored by a market capitalization of CNY 13.64 billion and an enterprise value of CNY 14.19 billion, all while its patent-rich, R&D‑heavy portfolio and foothold in telecommunications, medical equipment and defense-related high‑precision optics explain why institutional, PE and retail players alike are piling in-read on to see who is buying, how their stakes influence strategy, and why these specific investments matter for future revenue streams
Changchun UP Optotech Co.,Ltd. (002338.SZ) - Who Invests in Changchun UP Optotech Co.,Ltd. and Why?
Changchun UP Optotech Co.,Ltd. (002338.SZ) attracts a multi‑layered investor base drawn by its role in high‑precision optics, steady financials, and alignment with China's strategic tech priorities. The company's product set - optical lenses, optical‑mechanical subsystems, optical materials and modules - serves telecom, medical, instrumentation, aerospace and defense markets, creating cross‑sector demand stability and premium margins that appeal to different investor profiles.- Institutional investors: pension funds, mutual funds and state‑affiliated asset managers seeking exposure to China's domestic optoelectronics champions and technologies prioritized under national self‑reliance initiatives.
- Private equity and strategic investors: growth‑oriented funds and industrial buyers focused on scaling medical optics, specialty optical materials and vertical integration opportunities.
- Individual retail investors: domestic A‑share holders attracted by consistent top‑line growth, dividend prospects and participation in strategic supply chains.
| Metric | Value |
|---|---|
| Revenue (FY2023) | RMB 1.05 billion |
| Net profit (FY2023) | RMB 120 million |
| R&D expenditure (FY2023) | RMB 80 million (≈7.6% of revenue) |
| Total patents / IP families (granted + pending) | ≈420 |
| Institutional ownership (approx.) | ~42% |
| Free float / retail ownership (approx.) | ~30% |
| Top 10 shareholders (combined) | ~55% |
- Market position: leading niche supplier of optical‑mechanical subsystems with defensible customer relationships in medical, telecom and aerospace.
- Strategic fit: alignment with national industrial policies to reduce reliance on foreign optical components.
- Capital efficiency: above‑industry ROE and disciplined capex/R&D mix that supports margin resilience.
- Growth levers: expansion into higher‑margin medical equipment optics and advanced optical materials that can unlock new revenue streams.
- Consolidation potential: roll‑up synergies with downstream integrators or material suppliers to capture vertical value.
- IP leverage: monetize and defend technology via licensing, higher ASPs and premium OEM contracts.
- Steady growth story: multi‑year revenue expansion and periodic profitability improvements visible in quarterly disclosures.
- National strategic narrative: perceived beneficiary of policies favoring domestic supply chains in advanced optics.
- Dividend and share‑price upside expectations tied to new product ramps and export gains.
| Investor Type | Primary Return Driver | Primary Risk |
|---|---|---|
| Institutional | Market share growth + margin expansion | Technology substitution & cyclical demand in telecom |
| Private equity | Multiple expansion via operational scale & new product monetization | Execution risk on integration & regulatory approvals for medical products |
| Retail | Stock price appreciation on product wins | Volatility and concentration risk in component markets |
- Extensive patent portfolio (~420 families) protecting core lens designs and assembly processes.
- Sustained R&D intensity (≈7-9% of revenue in recent years) funding next‑gen optics and materials.
- Proven supply relationships with OEMs in medical imaging, instrumentation and certain defense applications requiring high precision.
| Investor Category | Typical Stake Size | Investment Horizon / Objective |
|---|---|---|
| Pension & mutual funds | 1-5% each; combined ~25-35% | Long‑term capital appreciation, dividend income |
| State‑affiliated asset managers | small single‑digit % stakes | Support domestic industrial strategy, stable holdings |
| Private equity / strategic partners | 5-15% (in deals) | Operational scaling, exit in 3-7 years |
Changchun UP Optotech Co.,Ltd. (002338.SZ) Institutional Ownership and Major Shareholders of Changchun UP Optotech Co.,Ltd. (002338.SZ)
As of September 29, 2025, institutional investors hold a substantial portion of Changchun UP Optotech Co.,Ltd.'s shares, reflecting notable professional investor confidence and strategic positioning ahead of related affiliate developments.
- Institutional ownership: 46.02% (as of 2025-09-29).
- Market capitalization: CNY 13.64 billion (2025-09-29).
- Enterprise value (EV): CNY 14.19 billion (2025-09-29).
- Largest related-party shareholder: Changchun UP Optotech Co., Ltd. holds a 25.56% stake in its affiliate Changchun Changguang Chenxin Microelectronics (the affiliate has submitted an H‑share listing application to the Hong Kong Stock Exchange).
Major shareholders and investor types (representative list):
- Changchun UP Optotech Co., Ltd. (affiliate stake holder) - 25.56% in Changchun Changguang Chenxin Microelectronics.
- Wuhu Tuochen Private Equity Investment Center (Limited Partnership) - major private equity investor (stake: N/A).
- Xiamen Yuanfeng Xinguang Enterprise Management Partnership (Limited Partnership) - major private equity investor (stake: N/A).
- Xianjin Zhizao Industry Investment Fund II (Limited Partnership) - major private equity investor (stake: N/A).
- Yibin Chendao New Energy Industry Equity Investment Partnership (Limited Partnership) - major private equity investor (stake: N/A).
- Individual retail shareholders - smaller proportion relative to institutions and PE (precise % N/A).
| Item | Value (as of 2025-09-29) |
|---|---|
| Institutional ownership | 46.02% |
| Market capitalization | CNY 13.64 billion |
| Enterprise value (EV) | CNY 14.19 billion |
| Largest related-party stake | Changchun UP Optotech's 25.56% stake in Changchun Changguang Chenxin Microelectronics |
| Notable private equity shareholders | Wuhu Tuochen PE, Xiamen Yuanfeng Xinguang, Xianjin Zhizao II, Yibin Chendao (stakes: N/A) |
Why institutional and PE investors are buying:
- Exposure to photonics/optoelectronics demand and downstream applications (displays, sensors, automotive lighting).
- Strategic upside from the affiliate's prospective H‑share listing (25.56% related-party holding enhances group value linkage).
- Private equity focus on operational improvements, scale-up financing, and value‑creation ahead of potential secondary listings or exits.
- Relative market size and valuation metrics: CNY 13.64B market cap vs. CNY 14.19B EV suggesting modest leverage/adjusted valuation profile.
Contextual resources: Changchun UP Optotech Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money
Changchun UP Optotech Co.,Ltd. (002338.SZ) - Key Investors and Their Impact on Changchun UP Optotech Co.,Ltd.
Changchun UP Optotech's shareholder and investor base combines a controlling affiliate stake, strategic private equity partners, and industry-focused funds that together have shaped capital access, R&D direction and business diversification. Notably, affiliate Changchun Changguang Chenxin Microelectronics holds a 25.56% stake and has filed for an H‑share listing on the HKEX-an event that could materially increase market visibility and liquidity for the group.- Affiliate/Controlling Investor: Changchun Changguang Chenxin Microelectronics - 25.56% stake; H‑share listing filed (HKEX) which can unlock valuation uplift, broaden investor base and ease cross‑border capital raises.
- Private equity backers: Wuhu Tuochen Private Equity Investment Center (LP) and Xiamen Yuanfeng Xinguang Enterprise Management Partnership (LP) - provided growth capital, board/strategic support and exit‑oriented value creation focus.
- Industry funds: Xianjin Zhizao Industry Investment Fund II (LP) and Yibin Chendao New Energy Industry Equity Investment Partnership (LP) - signal sectoral confidence in optoelectronics and new energy/medical applications.
| Investor | Type | Known Stake / Status | Primary Contribution |
|---|---|---|---|
| Changchun Changguang Chenxin Microelectronics | Affiliate / Controlling | 25.56% - H‑share filing (HKEX) | Capital access, consolidation of group strategy, potential valuation uplift via H‑shares |
| Wuhu Tuochen Private Equity Investment Center (LP) | Private equity | Undisclosed | Growth capital, management oversight, strategic M&A advisory |
| Xiamen Yuanfeng Xinguang Enterprise Management Partnership (LP) | Private equity | Undisclosed | Operational scaling, network access, fundraising support |
| Xianjin Zhizao Industry Investment Fund II (LP) | Industry investment fund | Undisclosed | Technology validation, sector expertise, co‑investment in R&D |
| Yibin Chendao New Energy Industry Equity Investment Partnership (LP) | Industry fund | Undisclosed | Support for new energy/medical product initiatives and supply chain partnerships |
- Capital and liquidity effects: The affiliate's H‑share filing is likely to increase free float and cross‑border investor interest; private equity investors improve readiness for scale‑up and potential secondary transactions.
- R&D and product mix: Strategic investors have funded expansion into medical equipment and optical materials-evidenced by new product lines, increased CAPEX in specialized production and partnerships with medical device OEMs.
- Market positioning: Backing from industry funds focused on new energy and advanced manufacturing strengthens the company's credibility in high‑growth optoelectronics niches and supports share of wallet gains with institutional customers.
Changchun UP Optotech Co.,Ltd. (002338.SZ) - Market Impact and Investor Sentiment
- H-share filing ripple effects: The filing for an H-share listing by Changchun Changguang Chenxin Microelectronics has been taken by the market as a positive signal for the broader Changchun optoelectronics cluster, raising expectations of a valuation uplift for Changchun UP Optotech.
- Revenue and growth trajectory: Consistent revenue growth and a strategic emphasis on high-precision optical components have reinforced investor confidence and improved the company's risk/reward profile.
- Institutional and private equity endorsement: The presence of reputable private equity backers among major shareholders has enhanced credibility, drawing additional institutional interest and improving secondary-market liquidity.
- Strategic financing and liquidity: Ongoing strategic investments and the H-share pursuit are expected to expand access to overseas capital, supporting R&D scale-up and potential M&A activity.
| Metric | Value | As of |
|---|---|---|
| Market Capitalization | CNY 13.64 billion | 2025-09-29 |
| Enterprise Value (EV) | CNY 14.19 billion | 2025-09-29 |
| Trailing 12‑month Revenue (TTM) | CNY 2.48 billion | 2025-06 |
| YoY Revenue Growth (most recent year) | ~16% | FY2024-FY2025 |
| 3‑year Revenue CAGR | ~18% | 2022-2025 |
| Major private equity / institutional stake (combined) | ~25% | Public filings 2025 |
- Investor sentiment drivers:
- Valuation arbitrage potential from H‑share comparables (higher P/E bands vs. A‑share peers).
- Visibility into long‑term demand for high‑precision optics across automotive LiDAR, industrial imaging, and consumer AR/VR.
- Balance‑sheet strength implied by market cap/EV metrics and improving margins, which reduces perceived execution risk.
- Risks and watchpoints:
- Timing and terms of the H‑share listing could materially affect dilution and foreign ownership limits.
- Execution risk on capacity expansion and maintaining ASPs amid competitive pressures.
Changchun UP Optotech Co.,Ltd. (002338.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.